🌟🇺🇸 #FDAApproval Alert🚨 📅 Aug 6, 2025 ➡️ The FDA has granted accelerated approval to dordaviprone (Modeyso) for H3 K27M-mutant diffuse midline glioma in pts ≥1 y/o with progression after prior therapy. This is the first systemic therapy approved for this indication. 🔬 🧪

In this editorial, authors strongly urge the entire #NeuroOnc community to rapidly recognize this rare population, thereby advancing knowledge and enabling the adequate management of patients and their family members. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert Angelo Dipasquale

Just launched: Neuro-Oncology Pediatrics! A new open-access journal dedicated to advancing care & research for children and AYAs with brain & nervous system tumors. Published by Oxford University Press and co-owned by EANO and SNO. soc-neuro-onc.org/WEB/About_Cont…

Is Re-RT beneficial for recurrent pontine glioma? YES, Re-RT only factor benefit OS on MVA Re-RT 75% have neuro symptom improvement

⚡ PROpel → VISION: ASCO 2025 mCRPC guideline redefines treatment 🩺 🔑 Highlights: 🧬 HRR testing = mandatory 20–30% of mCRPC have HRR mutations → guides PARPi use 🔹 BRCA1/2+ • Olaparib+Abi (PROpel) • Niraparib+Abi (MAGNITUDE) • Talazoparib+Enza (TALAPRO-2) 🔹 Non-BRCA

🌍 WHO’s review of 89K cancer trials (1999–2022) shows most studies are concentrated in high-income countries, high-mortality cancers remain under-studied, ph 3 trials are rare, and pediatric and older pts are underrepresented. 💬WHO calls for a fairer, more inclusive, and

Los días 28 y 29 de octubre de octubre celebraremos el XVII Simposio GEINO en ICOMEM. Contaremos con la participación del doctor Roger Stupp, neurooncólogo de renombre internacional. Consulta el programa aquí 👉 geino.es/wp-content/upl…

Optic nerve sheath meningioma study from Milan · 50 patients median F/U 6yrs · 25Gy/5 isodose 75-85% · Vision 4% worse, 60% stable, 32% ↑↑ · 100% LC sciencedirect.com/science/articl…

🚀 Outstanding results of adding #aspirin to PI3Kmut #CCR OncoAlert

Current National Comprehensive Cancer Network (NCCN) guidelines for germline testing. This is one place where we collectively need to do better not only to ensure we have the discussion for Rx options but this has profound impact on pts family! #OncTwitter #MedTwitter #MedEd #bcsm #lcsm #gusm #gism

Abiraterone 250mg vs. 1000mg? Multiple studies continue to show similar efficacy and ⬇️ cost (though through Mark Cuban Cost Plus Drug Company Mark Cuban, cost has gone ⬇️ significantly…), should the lower dose be the SoC in CRPC and higher dose be used as a back-up? #OncTwitter #gusm JCO Global Oncology

Can DOTATATE-Pet help diagnose Optic nerve sheath meningioma? YES according to these studies 56 yo initially diagnosed optic neuritis, yet older age, no MS, neg oligoclonal bands, prog ↓↓ vision on steroids. DOTATATE helpful w/ diagnosis ONSM journals.lww.com/nuclearmed/abs…

Información importante! 🧠 Nuevo ensayo clínico ➡️ estudio de fase 3 de Optune concomitante con temozolomida + pembrolizumab en glioblastoma de reciente diagnóstico (EF-41) Más detalles en > clinicaltrials.gov/study/NCT06556…

FDA new drug approvals in Q3 2025 nature.com/articles/d4157… Q3 saw a welcome bolus of novel FDA drug approvals, with the 16 approvals matching the 16 approvals in total in the first half of the year, including the first drug for bronchiectasis nature.com/articles/d4157…

ESMO HANDBOOK OF CANCER GENETICS AND GENOMICS #ESMO25 List of Actionable Genes and the FDA-approved Molecularly Matched Drugs👇

📢 #ESMO25 | #NETs COMPETE trial: ¹⁷⁷Lu-edotreotide vs everolimus in G1–2 GEP-NETs 🧩 mPFS 23.9 vs 14.1 mo | HR 0.67 (95% CI 0.48–0.95); p=0.022 🧩 ORR 22% vs 4% (p<0.0001) ⚕️ Drug-related discontinuations: 2% vs 15% 💡 ¹⁷⁷Lu-edotreotide outperforms everolimus, safer ✅

🚀 LAST Presidential III #ESMO25 🫴🏽 DYNAMIC-III 🩸 #ctDNA guided trial🤩 Great discussion by Tanios Bekaii-Saab, MD ❌ NOT a positive trial for #DFS ⁉️ #OS waiting, might be positive Is #prognostic information worth the cost and burden? OncoAlert ESMO - Eur. Oncology ASCO SEOM

Congratulations to all my colleagues from Vall d’Hebron Institute of Oncology (VHIO) Vall d'Hebron for today's presentation at the #poster session at #ESMO25 🙌🏽 Academic efforts are not easy to push forward, bravo👏🏽 OncoAlert SEOM

‼️🆕 Just published in JAMA Oncology: Consensus guidelines for the use of #NGS in #sarcoma pts: 🤔Little data supporting routine, nonselective use 🔬💊Potential benefit in selected entities 🏥Sarcoma experts are critical 🧬BUT we need more molecular data! ▶️jamanetwork.com/journals/jamao…

🧠 FDA Grants Orphan Drug Designation to Cintredekin Besudotox for Glioblastoma The IL13-PE38QQR agent advances as Precision NeuroMed pursues novel treatment strategies for this aggressive cancer. Read more: hubs.ly/Q03Q5PH20